These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 31758404)

  • 1. The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy.
    Ravindran S; Rasool S; Maccalli C
    Cancer Microenviron; 2019 Dec; 12(2-3):133-148. PubMed ID: 31758404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs.
    Tomei S; Ibnaof O; Ravindran S; Ferrone S; Maccalli C
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cancer stem cells in the modulation of anti-tumor immune responses.
    Maccalli C; Rasul KI; Elawad M; Ferrone S
    Semin Cancer Biol; 2018 Dec; 53():189-200. PubMed ID: 30261276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells.
    Khosravi N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Shahgoli VK; Hemmat N; Safarzadeh E; Baradaran B
    Life Sci; 2020 Sep; 256():118005. PubMed ID: 32593711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
    Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
    Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking Tumor Microenvironment to Plasticity of Cancer Stem Cells: Mechanisms and Application in Cancer Therapy.
    Zheng X; Yu C; Xu M
    Front Oncol; 2021; 11():678333. PubMed ID: 34262865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
    Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
    Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.
    Takeda R; Hirohashi Y; Shen M; Wang L; Ogawa T; Murai A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nishidate T; Okita K; Kutomi G; Sato N; Takemasa I; Torigoe T
    Biochem Biophys Res Commun; 2017 Apr; 485(3):651-657. PubMed ID: 28219643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of HSF1 at serine 326 residue is related to the maintenance of gynecologic cancer stem cells through expression of HSP27.
    Yasuda K; Hirohashi Y; Mariya T; Murai A; Tabuchi Y; Kuroda T; Kusumoto H; Takaya A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Hirano H; Hasegawa T; Saito T; Sato N; Torigoe T
    Oncotarget; 2017 May; 8(19):31540-31553. PubMed ID: 28415561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.
    Volonté A; Di Tomaso T; Spinelli M; Todaro M; Sanvito F; Albarello L; Bissolati M; Ghirardelli L; Orsenigo E; Ferrone S; Doglioni C; Stassi G; Dellabona P; Staudacher C; Parmiani G; Maccalli C
    J Immunol; 2014 Jan; 192(1):523-32. PubMed ID: 24277698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and Analysis of Cancer Stem-Like and Non-Cancer Stem-Like Clone Cells from the Human Colon Cancer Cell Line SW480.
    Takaya A; Hirohashi Y; Murai A; Morita R; Saijo H; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Takemasa I; Kondo T; Sato N; Torigoe T
    PLoS One; 2016; 11(7):e0158903. PubMed ID: 27415781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
    Miyata H; Hirohashi Y; Yamada S; Yanagawa J; Murai A; Hashimoto S; Tokita S; Hori K; Abe T; Kubo T; Tsukahara T; Kanaseki T; Shinohara N; Torigoe T
    Cancer Immunol Immunother; 2022 Apr; 71(4):795-806. PubMed ID: 34405274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.
    Ruiu R; Tarone L; Rolih V; Barutello G; Bolli E; Riccardo F; Cavallo F; Conti L
    Prog Mol Biol Transl Sci; 2019; 164():119-188. PubMed ID: 31383404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.
    Mori T; Nishizawa S; Hirohashi Y; Torigoe T; Tamura Y; Takahashi A; Kochin V; Fujii R; Kondo T; Greene MI; Hara I; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):27-32. PubMed ID: 22001602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.
    Li YR; Fang Y; Lyu Z; Zhu Y; Yang L
    J Transl Med; 2023 Oct; 21(1):686. PubMed ID: 37784157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway.
    Ogawa T; Hirohashi Y; Murai A; Nishidate T; Okita K; Wang L; Ikehara Y; Satoyoshi T; Usui A; Kubo T; Nakastugawa M; Kanaseki T; Tsukahara T; Kutomi G; Furuhata T; Hirata K; Sato N; Mizuguchi T; Takemasa I; Torigoe T
    Oncotarget; 2017 Dec; 8(68):112550-112564. PubMed ID: 29348846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    Morrison BJ; Steel JC; Morris JC
    BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis.
    Singh D; Khan MA; Siddique HR
    Biochem Pharmacol; 2022 Apr; 198():114955. PubMed ID: 35181312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy.
    Dianat-Moghadam H; Mahari A; Salahlou R; Khalili M; Azizi M; Sadeghzadeh H
    Stem Cell Res Ther; 2022 Apr; 13(1):150. PubMed ID: 35395787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.